Kerri Fitzgerald

DocwireNews

Trastuzumab deruxtecan demonstrated durable anti-tumor activity in previously treated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/denosumab-flops-in-breast-cancer-study/">breast cancer</a>, according to a study published in The New England Journal of Medicine&nbsp;and presented at the San Antonio Breast Cancer Symposium.The two-part, open-label, single-group, multicenter, phase II DESTINY-Breast01 study included 184 patients with HER2+ <a href="https://www.docwirenews.com/docwire-pick/3d-printing-breast-prosthetics-for-cancer-survivors-with-mastectomies/">metastatic breast cancer</a> who had received a median of six prior lines of therapy, including trastuzumab, trastuzumab emtansine,&nbsp;pertuzumab, and other targeted therapies. Patients received trastuzumab deruxtecan 5.4 mg/kg of body weight (recommended dose from phase I study).<h2>Response to treatment</h2>In the intention-to-treat analysis, 112 patients (60.9%) responded to trastuzumab deruxtecan therapy (95% CI, 53.4-68.0), including 11 (6.0%) complete responses and 101 (54.9%) partial responses. After a median follow-up of 11.1 months (range, 0.7-19.9 months), median duration of response was 14.8 months (95% CI, 13.8-16.9), and median time to response was 1.6 months (95% CI, 1.4-2.6).Median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached).Grade &ge;3 treatment-related adverse events (AEs) occurred in 57.1% of patients and included decreased neutrophil count (20.7%), anemia (8.7%), and nausea (7.6%). AEs resulted in dose interruptions in 65 patients (35.3%) and dose reductions in 43 patients (23.4%). A total of 28 patients (15.2%) discontinued treatment due to an AE, most commonly related to pneumonitis or interstitial lung disease (ILD).ILD occurred in 13.6% of patients (n=25), which the researchers said, &ldquo;requires attention to pulmonary symptoms and careful monitoring.&rdquo;

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Trastuzumab Deruxtecan Is a Potential Treatment Option for HER2+ Breast Cancer

Breast Cancer News

Trastuzumab deruxtecan demonstrated durable anti-tumor activity in previously treated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe